AVITA Medical (RCEL) said Monday that the US Food and Drug Administration has approved its premarket approval supplement for Recell Go Mini.
The Recell Go Mini disposable cartridge, which is a line extension of the Recell Go system, was designed specifically to treat smaller wounds of up to 480 square centimeters, the company said.
AVITA said the rollout will start with trauma and burn centers that treat smaller wounds during Q1 2025.
The shares of AVITA Medical rose 4.3% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。